\-\ Texto\\:\\ \ \(0\)\
\-\ labs\\ were\\ normal\\.\ \(2\)\
\-\ no\\ treatment\\ was\\ necessary\\ at\\ this\\ point\\.\\ \\ there\\ is\\ no\\ need\\ for\\ routine\\ follow\\-up\\ for\\ aml\\ \\<\\ 3cm\\,\\ unless\\ symptoms\\ arise\\.\\ \\ hemorrhage\\ is\\ the\\ most\\ common\\ complication\\ of\\ the\\ angiomyolipomas\\ \\-\\ and\\ lesions\\ larger\\ than\\ 3cm\\ may\\ be\\ resected\\ to\\ reduce\\ risk\\ of\\ hemorrhage\\.\ \(0\)\
\-\ images\\ demonstrate\\ bilateral\\ masses\\ arising\\ from\\ the\\ kidneys\\.\\ \\ the\\ masses\\ are\\ heterogeneous\\ in\\ density\\,\\ containing\\ soft\\ tissue\\ and\\ fatty\\ elements\\.\\ \\ portions\\ of\\ the\\ masses\\ enhance\\ upon\\ administration\\ of\\ iv\\ contrast\\.\\ incidentally\\,\\ the\\ mass\\ seen\\ in\\ the\\ lateral\\ right\\ kidney\\ demonstrates\\ regions\\ of\\ fat\\ attenuation\\ on\\ other\\ images\\.\\ \\ the\\ patient\\ also\\ demonstrates\\ multiple\\ calcified\\ subependymal\\ nodules\\ on\\ non\\-contrast\\ head\\ ct\\.\ \(0\)\
\-\ tuberous\\ sclerosis\\ \\(ts\\)\\,\\ renal\\ angiomyolipoma\\ \\(aml\\)\ \(0\)\
\-\ \\â\\€\\¢\\ lipoma\ \(1\)\
\-\ \\â\\€\\¢\\ angiomyolipoma\ \(2\)\
\-\ \\â\\€\\¢\\ renal\\ cell\\ carcinomas\ \(0\)\
\-\ \\â\\€\\¢\\ lymphoma\ \(6\)\
\-\ \\â\\€\\¢\\ metastases\ \(0\)\
\-\ 23\\ y\\.o\\.\\ man\\ with\\ a\\ known\\ disease\\ had\\ these\\ images\\ obtained\\ for\\ routine\\ follow\\-up\\.\\ \\ he\\ was\\ asymptomatic\\.\ \(0\)\
\-\ the\\ macroscopic\\ fat\\ within\\ these\\ bilateral\\ masses\\ makes\\ them\\ consistent\\ with\\ angiomyolipomas\\.\\ \\ rarely\\,\\ renal\\ cell\\ carcinomas\\ may\\ engulf\\ adjacent\\ fat\\.\\ \\ neither\\ lymphoma\\ nor\\ metastases\\ would\\ be\\ expected\\ to\\ contain\\ fat\\.\\ \\ the\\ bilateral\\ nature\\ of\\ the\\ lesions\\ is\\ consistent\\ with\\ tuberous\\ sclerosis\\.\\ \\ this\\ patient\\ also\\ displayed\\ multiple\\ calcified\\ subependymal\\ nodules\\ or\\ tubers\\ within\\ the\\ ventricular\\ system\\ of\\ the\\ brain\\,\\ an\\ additional\\ finding\\ associated\\ with\\ tuberous\\ sclerosis\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ tuberous\\:\\ 0\\.2405270067491155\ \(0\)\
\-\ masses\\:\\ 0\\.21893585437733218\ \(0\)\
\-\ the\\:\\ 0\\.20855216231855592\ \(0\)\
\-\ fat\\:\\ 0\\.2000520593623556\ \(0\)\
\-\ angiomyolipomas\\:\\ 0\\.19853398185931923\ \(0\)\
\-\ aml\\:\\ 0\\.19368977662779036\ \(0\)\
\-\ carcinomas\\:\\ 0\\.17989013433114484\ \(0\)\
\-\ angiomyolipoma\\:\\ 0\\.1720090495050899\ \(0\)\
\-\ sclerosis\\:\\ 0\\.1717989469256334\ \(0\)\
\-\ subependymal\\:\\ 0\\.17132977507446662\ \(0\)\
\-\ 3cm\\:\\ 0\\.16815918664770668\ \(0\)\
\-\ renal\\:\\ 0\\.15019981576952826\ \(0\)\
\-\ metastases\\:\\ 0\\.12999589622629454\ \(0\)\
\-\ bilateral\\:\\ 0\\.1296278473643153\ \(0\)\
\-\ calcified\\:\\ 0\\.12953503814406428\ \(0\)\
\-\ nodules\\:\\ 0\\.1277634484522974\ \(0\)\
\-\ routine\\:\\ 0\\.12452292459559709\ \(0\)\
\-\ engulf\\:\\ 0\\.11880578742806076\ \(0\)\
\-\ images\\:\\ 0\\.11156939442809964\ \(0\)\
\-\ of\\:\\ 0\\.11013582646282204\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.10765802936182954\ \(0\)\
\-\ ts\\:\\ 0\\.10454801872811759\ \(0\)\
\-\ tubers\\:\\ 0\\.10332165754846694\ \(0\)\
\-\ lymphoma\\:\\ 0\\.09576492859622865\ \(0\)\
\-\ displayed\\:\\ 0\\.09477862047891701\ \(0\)\
\-\ neither\\:\\ 0\\.09355225929926635\ \(0\)\
\-\ lesions\\:\\ 0\\.09234788687505863\ \(0\)\
\-\ cell\\:\\ 0\\.09198363669067854\ \(0\)\
\-\ macroscopic\\:\\ 0\\.09137961916762657\ \(0\)\
\-\ these\\:\\ 0\\.09080238041438585\ \(0\)\
\-\ them\\:\\ 0\\.0874513593369944\ \(0\)\
\-\ consistent\\:\\ 0\\.08718815107080442\ \(0\)\
\-\ reduce\\:\\ 0\\.08186417846315534\ \(0\)\
\-\ may\\:\\ 0\\.08091842361427212\ \(0\)\
\-\ demonstrates\\:\\ 0\\.08078296672308147\ \(0\)\
\-\ makes\\:\\ 0\\.08063781728350468\ \(0\)\
\-\ contain\\:\\ 0\\.08040484896440656\ \(0\)\
\-\ elements\\:\\ 0\\.07972819443125843\ \(0\)\
\-\ unless\\:\\ 0\\.0790825428097092\ \(0\)\
\-\ multiple\\:\\ 0\\.07864960674477506\ \(0\)\
\-\ nor\\:\\ 0\\.07826525518414658\ \(0\)\
\-\ contrast\\:\\ 0\\.07812827174322608\ \(0\)\
\-\ fatty\\:\\ 0\\.07640806440808658\ \(0\)\
\-\ portions\\:\\ 0\\.07640806440808658\ \(0\)\
\-\ also\\:\\ 0\\.07563458363799483\ \(0\)\
\-\ within\\:\\ 0\\.07405841706278594\ \(0\)\
\-\ need\\:\\ 0\\.07401346280086518\ \(0\)\
\-\ arise\\:\\ 0\\.0735797589689299\ \(0\)\
\-\ resected\\:\\ 0\\.0735797589689299\ \(0\)\
\-\ for\\:\\ 0\\.07310477864885047\ \(0\)\
\-\ complication\\:\\ 0\\.07302149738291944\ \(0\)\
\-\ expected\\:\\ 0\\.07248450815247104\ \(0\)\
\-\ containing\\:\\ 0\\.0722234958337194\ \(0\)\
\-\ larger\\:\\ 0\\.07196722945740054\ \(0\)\
\-\ enhance\\:\\ 0\\.07196722945740054\ \(0\)\
\-\ rarely\\:\\ 0\\.07171553951180835\ \(0\)\
\-\ nature\\:\\ 0\\.07098636334104423\ \(0\)\
\-\ lipoma\\:\\ 0\\.06974027610861923\ \(0\)\
\-\ kidneys\\:\\ 0\\.06920835402271817\ \(0\)\
\-\ regions\\:\\ 0\\.0690010817224178\ \(0\)\
\-\ incidentally\\:\\ 0\\.06849585693494599\ \(0\)\
\-\ ventricular\\:\\ 0\\.06762972533909431\ \(0\)\
\-\ necessary\\:\\ 0\\.06726122690061016\ \(0\)\
\-\ point\\:\\ 0\\.06646572825414379\ \(0\)\
\-\ 23\\:\\ 0\\.06629488661807603\ \(0\)\
\-\ is\\:\\ 0\\.06605327365589206\ \(0\)\
\-\ be\\:\\ 0\\.06522915879745612\ \(0\)\
\-\ administration\\:\\ 0\\.06402554447822596\ \(0\)\
\-\ arising\\:\\ 0\\.0638817242261487\ \(0\)\
\-\ upon\\:\\ 0\\.06325209913371883\ \(0\)\
\-\ with\\:\\ 0\\.06297236148165124\ \(0\)\
\-\ additional\\:\\ 0\\.06232538196475418\ \(0\)\
\-\ attenuation\\:\\ 0\\.06151621757348893\ \(0\)\
\-\ system\\:\\ 0\\.06133590472095322\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.058190860954392146\ \(0\)\
\-\ risk\\:\\ 0\\.057446436462716674\ \(0\)\
\-\ iv\\:\\ 0\\.057446436462716674\ \(0\)\
\-\ would\\:\\ 0\\.056912835988911684\ \(0\)\
\-\ obtained\\:\\ 0\\.056869267909685405\ \(0\)\
\-\ kidney\\:\\ 0\\.056483099577806714\ \(0\)\
\-\ was\\:\\ 0\\.056039556271529234\ \(0\)\
\-\ labs\\:\\ 0\\.05570102748211467\ \(0\)\
\-\ this\\:\\ 0\\.05525295177843836\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.054733963594333045\ \(0\)\
\-\ density\\:\\ 0\\.05331268359484094\ \(0\)\
\-\ finding\\:\\ 0\\.052847264717795134\ \(0\)\
\-\ patient\\:\\ 0\\.05229938771170276\ \(0\)\
\-\ no\\:\\ 0\\.05228955050175712\ \(0\)\
\-\ adjacent\\:\\ 0\\.05211451658823802\ \(0\)\
\-\ known\\:\\ 0\\.052052563686699596\ \(0\)\
\-\ brain\\:\\ 0\\.05012040021649782\ \(0\)\
\-\ on\\:\\ 0\\.04856363585377265\ \(0\)\
\-\ head\\:\\ 0\\.04795161045024372\ \(0\)\
\-\ he\\:\\ 0\\.04760922286661297\ \(0\)\
\-\ common\\:\\ 0\\.045595329122485234\ \(0\)\
\-\ than\\:\\ 0\\.04557579445212786\ \(0\)\
\-\ symptoms\\:\\ 0\\.043989669576457585\ \(0\)\
\-\ soft\\:\\ 0\\.04280261078065091\ \(0\)\
\-\ man\\:\\ 0\\.042564123493180506\ \(0\)\
\-\ associated\\:\\ 0\\.042376197210299886\ \(0\)\
\-\ tissue\\:\\ 0\\.04217539884273008\ \(0\)\
\-\ most\\:\\ 0\\.04184197063413755\ \(0\)\
\-\ demonstrate\\:\\ 0\\.04179710822255205\ \(0\)\
\-\ other\\:\\ 0\\.04175238815624519\ \(0\)\
\-\ were\\:\\ 0\\.041443258782171484\ \(0\)\
\-\ to\\:\\ 0\\.040199084647768585\ \(0\)\
\-\ had\\:\\ 0\\.04005763870569412\ \(0\)\
\-\ in\\:\\ 0\\.04000122483638743\ \(0\)\
\-\ lateral\\:\\ 0\\.03990015927511642\ \(0\)\
\-\ treatment\\:\\ 0\\.038298215015610405\ \(0\)\
\-\ seen\\:\\ 0\\.03785110453990849\ \(0\)\
\-\ disease\\:\\ 0\\.03374856047254195\ \(0\)\
\-\ and\\:\\ 0\\.03322685581762698\ \(0\)\
\-\ normal\\:\\ 0\\.03282629135438976\ \(0\)\
\-\ there\\:\\ 0\\.03199043340465969\ \(0\)\
\-\ from\\:\\ 0\\.031930995204153184\ \(0\)\
\-\ an\\:\\ 0\\.030744231627107835\ \(0\)\
\-\ mass\\:\\ 0\\.030710195719703896\ \(0\)\
\-\ ct\\:\\ 0\\.030608578391223492\ \(0\)\
\-\ are\\:\\ 0\\.030507688465745426\ \(0\)\
\-\ at\\:\\ 0\\.030367644961765538\ \(0\)\
\-\ or\\:\\ 0\\.027969311258029133\ \(0\)\
\-\ right\\:\\ 0\\.026655529100896573\ \(0\)\
